The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Eszopiclone Coadministered With Escitalopram in Patients With Insomnia and Comorbid Generalized Anxiety Disorder
Abstract
CONTEXT: Insomnia and generalized anxiety disorder (GAD) are prevalent disorders that may coexist. OBJECTIVE: To determine the efficacy of eszopiclone combined with escitalopram oxalate in treating insomnia comorbid with GAD. DESIGN: Double-blind, randomized, placebo-controlled, parallel-group, add-on therapy 10-week study. SETTING: Multicenter outpatient study from July 2005 to April 2006. PATIENTS: Adults aged 18 to 64 years meeting DSM-IV-TR criteria for GAD and insomnia. INTERVENTIONS: Patients received 10 mg of escitalopram oxolate for 10 weeks and were randomized to also receive either 3 mg of eszopiclone (n = 294) or placebo (n = 301) nightly for 8 weeks. For the last 2 weeks, eszopiclone was replaced with a single-blind placebo. MAIN OUTCOME MEASURES: Sleep, daytime functioning, psychiatric measures, and adverse events. RESULTS: Compared with treatment with placebo and escitalopram, treatment with eszopiclone and escitalopram resulted in significantly improved sleep and daytime functioning (P < .05), with no evidence of tolerance. Patients taking eszopiclone and escitalopram had greater improvements in total Hamilton Anxiety Scale (HAM-A) scores at each week (P < .05) and at weeks 4 through 10 with the insomnia item removed. Clinical Global Impressions (CGI) of Improvement scores were improved with eszopiclone and escitalopram at every point (P < .02), while CGI of Severity of Illness scores were not significantly different after week 1. The HAM-A response (63% vs 49%, respectively, P = .001) and remission (42% vs 36%, respectively, P = .09) rates at week 8 were higher in patients treated with eszopiclone and escitalopram than those treated with placebo and escitalopram, and median time to onset of anxiolytic response was significantly reduced (P < or = .05). After eszopiclone discontinuation, there was no evidence of rebound insomnia, and while treatment differences in anxiety measures were maintained, differences in sleep outcomes were not. Overall adverse event rates were 77.6% with cotherapy and 67.9% with monotherapy. The most common adverse events with cotherapy were unpleasant taste, headache, dry mouth, and somnolence. CONCLUSIONS: Coadministration of eszopiclone and escitalopram was well tolerated and associated with significantly improved sleep, daytime functioning, anxiety, and mood in patients with insomnia and GAD. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00235508.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Validation of the Insomnia Severity Index as an outcome measure for insomnia research
Bastien, C. (2001) · Sleep Medicine · doi:10.1016/s1389-9457(00)00065-4 · Cited by 8,067
Epidemiologic Study of Sleep Disturbances and Psychiatric Disorders: An Opportunity for Prevention?
Ford, D. E. (1989) · JAMA · doi:10.1001/jama.1989.03430110069030 · Cited by 2,252
Sleep and Psychiatric Disorders: A Meta-analysis
Benca, R. M. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080059010 · Cited by 1,468
Place of chronic insomnia in the course of depressive and anxiety disorders
Ohayon, M. M., & Roth, T. (2003) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(02)00052-3 · Cited by 873
Self-citationJohnson, E. O., Roth, T., & Breslau, N. (2006) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.07.008 · Cited by 804
Self-citationFava, M., McCall, W. V., Krystal, A., Wessel, T., Rubens, R., Caron, J., Amato, D., & Roth, T. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.01.016 · Cited by 480
Ohayon, M. M. (1997) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(97)00002-2 · Cited by 423
ROTH, T., WALSH, J., KRYSTAL, A., WESSEL, T., & ROEHRS, T. (2005) · Sleep Medicine · doi:10.1016/j.sleep.2005.06.004 · Cited by 230
Self-citationSleep disturbance in generalized anxiety disorder and its treatment
Monti, J. M., & Monti, D. (2000) · Sleep Medicine Reviews · doi:10.1053/smrv.1999.0096 · Cited by 223
Zolpidem for Persistent Insomnia in SSRI-Treated Depressed Patients
Asnis, G. M., Chakraburtty, A., DuBoff, E. A., Krystal, A., Londborg, P. D., Rosenberg, R., Roth-Schechter, B., Scharf, M. B., & Walsh, J. K. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n1005 · Cited by 176
Self-citationWetherell, J. L., Le Roux, H., & Gatz, M. (2003) · Psychology and Aging · doi:10.1037/0882-7974.18.3.622 · Cited by 103
Simon, N. M., Zalta, A. K., Worthington III, J. J., Hoge, E. A., Christian, K. M., Stevens, J. C., & Pollack, M. H. (2006) · Depression and Anxiety · doi:10.1002/da.20184 · Cited by 40
FONTAINE, R., BEAUDRY, P., MORVAN, P. L., BEAUCLAIR, L., & CHOUINARD, G. (1990) · International Clinical Psychopharmacology · doi:10.1097/00004850-199007000-00002 · Cited by 37
Cited by
Morin, C. M., & Benca, R. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60750-2 · Cited by 976
The GABA system in anxiety and depression and its therapeutic potential
Möhler, H. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.040 · Cited by 590
Sleep and anxiety: From mechanisms to interventions
Chellappa, S. L., & Aeschbach, D. (2022) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2021.101583 · Cited by 509
Psychiatric Disorders and Sleep
Krystal, A. D. (2012) · Neurologic Clinics · doi:10.1016/j.ncl.2012.08.018 · Cited by 386
Self-citationWolff, A., Joshi, R. K., Ekström, J., Aframian, D., Pedersen, A. M. L., Proctor, G., Narayana, N., Villa, A., Sia, Y. W., Aliko, A., et al. (2017) · Drugs in R&D · doi:10.1007/s40268-016-0153-9 · Cited by 364
Metadata
- Authors
- Pollack, M., Kinrys, G., Krystal, A., McCall, W. V., Roth, T., Schaefer, K., Rubens, R., Roach, J., Huang, H., & Krishnan, R.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2008-05-01
- Volume
- 65
- Issue
- 5
- Pages
- 551
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2138362387
- Cited by
- 158
- References
- 14
- FWCI
- 21.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.